BEAM Healthcare

Beam Therapeutics Inc.

$26.33+1.78%

Price as of close on Nov 3, 2026 · Financials updated Oct 6, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 2.7B USD
Enterprise value: 1.4B USD
Full-time employees: 540

Overall health

Strength: growing faster than most peersgrowing faster than peers
Strength: lower risk than most peers: more short-term liquidity and less debt relative to equitylower risk: more liquidity and less debt vs equity
Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: its share price swings more than most peers’ (beta 2.20 vs a peer median of 0.63)bigger price swings (beta 2.20 vs peers 0.63)

Ranks #625 of 1,157 healthcare companies (bottom 47%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 45% from December 2022 to July 2026.
Beam Therapeutics had 45% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Beam Therapeutics had 45% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Stock-based pay is a large cost. Stock pay was 67% of revenue in 2025.
Beam Therapeutics paid employees $94M in stock in 2025, 67% of its $140M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Beam Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Growing fast, still losing money. Revenue grew faster than 95% of peers, at an operating loss.
Revenue grew faster than 95% of peers, but the business runs at an operating loss (margin -242%).

StockQuotient Score

50/ 100

Oct 5 50 → Nov 4 50

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-3.2%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-21.5%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-13.7%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield39.3%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

92/100

Strong

3/3 inputs reported · High confidence

Since last quarter: ▼ Weaker

12-month revenue fell 4.9%

Why

Stronger than most peers on:

▲ Revenue growth
▲ 3-yr revenue

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Still loss-making, but the loss per share narrowed33% base weight · Z-score 0.29Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth24.9%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score 2.26Sector median: 0.0584 · MAD: 0.0840

Revenue growth158.9%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score 10.15Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

14/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Operating margin
▼ ROIC
▼ ROA

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-242.3%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -20.48Sector median: 0.0706 · MAD: 0.1217

Return on assets-6.2%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -1.47Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-31.5%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -3.61Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin-161.9%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsOutlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-8.1%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Current ratio
▲ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta2.20

Yahoo Finance · 5-year monthly beta vs the marketOutlier capped at sector 5th/95th percentile33% base weight · Z-score -4.28Sector median: 0.6250 · MAD: 0.3380

Current ratio14.57×

SEC filings · latest balance sheetReported value33% base weight · Z-score 8.65Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.09×

SEC filings · latest balance sheetReported value33% base weight · Z-score 0.63Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Beam Therapeutics

Is Beam Therapeutics getting weaker?: Its latest SEC filing (Aug 4, 2026) got weaker in some ways: 12-month revenue fell 4.9%. Its overall score is unchanged at 50/100 since Oct 28, 2026.
How is Beam Therapeutics valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -3.2% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -3.2% vs peers 1.5% (weaker than 100% of peers).
Is Beam Therapeutics growing?: Yes, faster than most of its peers. Growth scores 92/100 against 1,393 healthcare peers. Revenue growth 158.9% vs a peer median of 6.1% (stronger than 95% of peers).Revenue growth 158.9% vs peers 6.1% (stronger than 95% of peers).
How profitable is Beam Therapeutics?: Less profitable than most of its peers. Profitability scores 14/100 against 1,393 healthcare peers. Operating margin -242.3% vs a peer median of 7.1% (weaker than 91% of peers).Operating margin -242.3% vs peers 7.1% (weaker than 91% of peers).
How risky is Beam Therapeutics?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 14.57× vs a peer median of 2.59× (stronger than 92% of peers).Current ratio 14.57× vs peers 2.59× (stronger than 92% of peers). Beta 2.20 vs a peer median of 0.63 (weaker than 100% of peers).Beta 2.20 vs peers 0.63 (weaker than 100% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 4, 2026 · compared with the quarter ended Mar 31, 2026

Got weaker

12-month revenue fell 4.9%

Worth watching: Beam Therapeutics is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Revenue (12 months)	164.0M USD	156.0M USD	−4.9%
Net income (12 months)	−66.0M USD	−86.5M USD	+31.1%
Operating margin	-226.6%	-242.3%	−15.7 pts
Free cash flow (12 months)	−383.8M USD	−372.8M USD	−2.9%
Debt	100.2M USD	100.3M USD	+0.1%
Cash	288.3M USD	219.8M USD	−23.7%
Shares outstanding	102.9M	103.3M	+0.4%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Operating margin	-757.0%	-555.6%	-46.7%	-654.3%	-274.6%	▲ 380 pts
Net margin	-714.9%	-474.5%	-35.1%	-593.1%	-57.2%	▲ 536 pts
Return on assets (ROA)	-25.1%	-21.5%	-9.1%	-34.1%	-5.4%	▲ 29 pts
Return on equity (ROE)	-44.8%	-39.4%	-13.5%	-51.4%	-6.5%	▲ 45 pts
Free cash flow margin	-218.1%	-43.4%	-48.4%	-560.8%	-257.7%	▲ 303 pts
Current ratio	5.96×	4.89×	5.89×	4.82×	13.09×	▲ 171%

BEAM price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: growing faster than most peersgrowing faster than peers

Strength: lower risk than most peers: more short-term liquidity and less debt relative to equitylower risk: more liquidity and less debt vs equity

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: its share price swings more than most peers’ (beta 2.20 vs a peer median of 0.63)bigger price swings (beta 2.20 vs peers 0.63)

Ranks #625 of 1,157 healthcare companies (bottom 47%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 45% from December 2022 to July 2026.

Beam Therapeutics had 45% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Beam Therapeutics had 45% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Stock-based pay is a large cost. Stock pay was 67% of revenue in 2025.

Beam Therapeutics paid employees $94M in stock in 2025, 67% of its $140M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Beam Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Growing fast, still losing money. Revenue grew faster than 95% of peers, at an operating loss.

Revenue grew faster than 95% of peers, but the business runs at an operating loss (margin -242%).

Questions investors ask about Beam Therapeutics

Is Beam Therapeutics getting weaker?

Its latest SEC filing (Aug 4, 2026) got weaker in some ways: 12-month revenue fell 4.9%. Its overall score is unchanged at 50/100 since Oct 28, 2026.

How is Beam Therapeutics valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -3.2% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -3.2% vs peers 1.5% (weaker than 100% of peers).

Is Beam Therapeutics growing?

Yes, faster than most of its peers. Growth scores 92/100 against 1,393 healthcare peers. Revenue growth 158.9% vs a peer median of 6.1% (stronger than 95% of peers).Revenue growth 158.9% vs peers 6.1% (stronger than 95% of peers).

How profitable is Beam Therapeutics?

Less profitable than most of its peers. Profitability scores 14/100 against 1,393 healthcare peers. Operating margin -242.3% vs a peer median of 7.1% (weaker than 91% of peers).Operating margin -242.3% vs peers 7.1% (weaker than 91% of peers).

How risky is Beam Therapeutics?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 14.57× vs a peer median of 2.59× (stronger than 92% of peers).Current ratio 14.57× vs peers 2.59× (stronger than 92% of peers). Beta 2.20 vs a peer median of 0.63 (weaker than 100% of peers).Beta 2.20 vs peers 0.63 (weaker than 100% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

164.0M USD

156.0M USD

−4.9%

Net income (12 months)

−66.0M USD

−86.5M USD

+31.1%

Operating margin

-226.6%

-242.3%

−15.7 pts

Free cash flow (12 months)

−383.8M USD

−372.8M USD

−2.9%

Debt

100.2M USD

100.3M USD

+0.1%

Cash

288.3M USD

219.8M USD

−23.7%

Shares outstanding

102.9M

103.3M

+0.4%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Operating margin

-757.0%

-555.6%

-46.7%

-654.3%

-274.6%

▲ 380 pts

Net margin

-714.9%

-474.5%

-35.1%

-593.1%

-57.2%

▲ 536 pts

Return on assets (ROA)

-25.1%

-21.5%

-9.1%

-34.1%

-5.4%

▲ 29 pts

Return on equity (ROE)

-44.8%

-39.4%

-13.5%

-51.4%

-6.5%

▲ 45 pts

Free cash flow margin

-218.1%

-43.4%

-48.4%

-560.8%

-257.7%

▲ 303 pts

Current ratio

5.96×

4.89×

5.89×

4.82×

13.09×

▲ 171%